|Day Low/High||91.64 / 94.23|
|52 Wk Low/High||82.50 / 167.92|
The pharmaceutical company is reportedly up for sale after being dogged by Starboard Value for months, and could go for up to $41 million.
Here's a technical look at how to trade some of the most active stocks on the market right now.
Stocks rise Monday after Federal Reserve Gov. Lael Brainard urges 'prudence' in raising rates.
Stocks climbed, though worries over how soon the Federal Reserve might hike interest rates kept markets wary.
The activist fund says Perrigo's promises over the past year have been "woefully unfulfilled."
Stocks pare gains on Monday as worries over how soon the Federal Reserve might hike interest rates keeps markets wary.
Perrigo is the second drug company that the activist has targeted in recent months after it rejected an unsolicited bid.
Falling crude oil prices continued to weigh on markets Monday.
Stock futures moved sharply lower on Monday morning, extending Friday's selloff, as worries continued over how soon the Federal Reserve might hike interest rates.
Starboard Value disclosed a 4.6% stake in Perrigo (PRGO) stock, and now wants the company to explore a sale of its prescription pharmaceuticals business.
Believes Company Currently Trades at a Significant Discount to Fair Value and That Substantial Opportunities Exist to Create Value for the Benefit of All Shareholders
David Einhorn's Greenlight Capital initiated positions in these stocks in the second quarter. Here's a technical look at how to trade them now.
David Einhorn is a man of many talents, including playing poker -- and watching where he stacks his chips investment-wise is a worthwhile endeavor, too.
Deutsche Bank lowered its price target to $105 on Perrigo (PRGO) stock this morning.
U.S. stocks edged back from records highs set last week as resurfacing supply worries took a chunk out of crude prices.
Ralph Lauren shares surge on earnings beat amid lethargic market action.
Perrigo (PRGO) posted weak earnings for the 2016 second quarter and cut its full-year forecast, which Jim Cramer found 'disturbing.'
Despite cutting its full year guidance, the company continues to have a lot of potential upside.
Perrigo might have been in more of a decline than the market realized when it turned down Mylan's $26 billion offer for the company last year, says Jim Cramer.
I'm not inclined to make market calls, but the action on my screen is pushing me to a defensive stance.
The stock's tumbling to near a 52-week low, but charts suggest caution.
Perrigo (PRGO) reported earnings for the 2016 second quarter, falling short of estimates and cutting guidance for the year.